Bristol Myers Squibb’s ongoing research in non-small cell lung cancer (NSCLC) has yielded promising results in various stages of the disease.
Perioperative Opdivo in Early-Stage NSCLC
Updated data from the CheckMate -77T study demonstrate the effectiveness of perioperative Opdivo in improving event-free survival in resectable stage III NSCLC patients, regardless of the number of lymph nodes affected. The Opdivo regimen significantly extended this critical endpoint compared to neoadjuvant chemotherapy and placebo.
Neoadjuvant Opdivo in Resectable NSCLC
A four-year follow-up analysis from the CheckMate -816 study reinforces the benefits of neoadjuvant Opdivo plus chemotherapy in patients with resectable NSCLC. This combination therapy showed efficacy in improving pathological complete response, indicating a lack of detectable cancer cells after surgery.
Opdivo Combinations in Advanced NSCLC
Five-year follow-up data from the CheckMate -9LA study highlight the impact of Opdivo plus Yervoy and chemotherapy in improving survival outcomes for patients with previously untreated metastatic NSCLC. This combination therapy significantly extended overall survival compared to chemotherapy alone.
Expanding the Lung Cancer Portfolio
Bristol Myers Squibb’s ongoing research extends beyond immunotherapy to include targeted approaches. An updated analysis from the TRIDENT-1 study shows Augytro’s durable response in ROS1-positive NSCLC patients. Additionally, the KRYSTAL-12 study demonstrated Krazati’s efficacy in improving progression-free survival in KRASG12C-mutated NSCLC patients.
These findings underscore the company’s commitment to providing innovative treatment options for patients with NSCLC, both in early and advanced stages. The expanding thoracic portfolio offers hope and the possibility of improved survival outcomes.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
